Gastric Cancer - KOL Insight

From the evolving role of Herceptin and trastuzumab biosimilars in first-line therapy to the promising potential of Enhertu in second-line treatment, this report delves into the latest advancements in gastric cancer therapies. Leading KOLs provide a thorough analysis of current treatments and emerging options, highlighting key challenges and future opportunities. Discover how these insights are set to transform the gastric cancer treatment landscape.

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

Marketed treatments

• Chemotherapy regimens, current treatment trends, challenges and unmet needs
  • Herceptin (trastuzumab; Roche)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
  • Cyramza (ramucirumab; Lilly)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo (nivolumab; BMS/Ono)

Late-stage pipeline programmes (120)

• Immunotherapies
  • Durvalumab (Imfinzi; AstraZeneca)
  • Avelumab (Bavencio; Merck Group/Pfizer)
  • Atezolizumab (Tecentriq; Roche)
• Targeted biologic therapies
  • Zolbetuximab (IMAB362/claudiximab; Astellas/Ganymed)
  • Margetuximab/retifanlimab/tebotelimab (MacroGenics/Incyte)
  • Bemarituzumab (Five Prime Therapeutics/Amgen)
  • Zanidatamab (ZW25; Zymeworks)
  • Evorpacept (ALX Oncology)
  • Catumaxomab (Removab; LintonPharm)
  • ARX788 (Ambrx/Zhejiang Medicine)
• Targeted oral therapies
  • Stivarga (regorafenib; Bayer)
• Next-generation therapies
  • Sirexatamab (DKN-01; Leap Therapeutics/BeiGene)

Future treatment trends

• Cell therapies and gastric cancer vaccines
  • Other promising technologies in the pipeline for gastric cancer

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe

News